Literature DB >> 36181622

Construction of TSC2 knockout cell line using CRISPR/Cas9 system and demonstration of its effects on NIH-3T3 cells.

Xu Wang1, Yang Zhao1, Zhan Wang1, Zhangcheng Liao1, Yushi Zhang2.   

Abstract

Tuberous sclerosis complex (TSC) is a rare autosomal dominant disorder involving multiple organ systems. TSC2 gene plays an important role in the development of TSC. The most common kidney manifestation of TSC is renal angiomyolipoma (RAML). TSC-RAML is more likely to be bilateral multiple tumors and tends to destroy the renal structure and damages renal function severely. As a result, patients with TSC-RAML often miss the opportunity for surgical treatment when TSC-RAML is diagnosed, causing difficulty in obtaining tumor specimens through surgery. Due to this difficulty, model cell lines must be constructed for scientific research. In this paper, TSC2 was knocked out in NIH-3T3 cell lines by CRISPR/Cas9 system. PCR, WB and mTOR inhibitor drug sensitivity test showed that the TSC2 knockout NIH-3T3 cells were successfully constructed. The ability of proliferation and invasion in TSC2 KO NIH-3T3 cells were higher than those in wild type group. The constructed KO cell line lay the foundation for further study of TSC.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  CRISPR/Cas9; Invasion; Knockout; NIH-3T3; Proliferation; TSC

Mesh:

Substances:

Year:  2022        PMID: 36181622     DOI: 10.1007/s12013-022-01094-0

Source DB:  PubMed          Journal:  Cell Biochem Biophys        ISSN: 1085-9195            Impact factor:   2.989


  33 in total

1.  Epidemiology of tuberous sclerosis.

Authors:  J P Osborne; A Fryer; D Webb
Journal:  Ann N Y Acad Sci       Date:  1991       Impact factor: 5.691

Review 2.  Renal disease in tuberous sclerosis complex: pathogenesis and therapy.

Authors:  Hilaire C Lam; Brian J Siroky; Elizabeth P Henske
Journal:  Nat Rev Nephrol       Date:  2018-11       Impact factor: 28.314

Review 3.  Pulmonary manifestations in tuberous sclerosis complex.

Authors:  Nishant Gupta; Elizabeth P Henske
Journal:  Am J Med Genet C Semin Med Genet       Date:  2018-07-28       Impact factor: 3.908

4.  Everolimus for severe arrhythmias in tuberous sclerosis complex related cardiac rhabdomyomas.

Authors:  María P Silva-Sánchez; Jorge L Alvarado-Socarras; Javier Castro-Monsalve; Keyla Milena Meneses; Justo Santiago; Carlos E Prada
Journal:  Am J Med Genet A       Date:  2021-02-16       Impact factor: 2.802

Review 5.  Tuberous sclerosis complex.

Authors:  Elizabeth P Henske; Sergiusz Jóźwiak; J Christopher Kingswood; Julian R Sampson; Elizabeth A Thiele
Journal:  Nat Rev Dis Primers       Date:  2016-05-26       Impact factor: 52.329

Review 6.  Renal angiomyolipoma with tuberous sclerosis complex: How it differs from sporadic angiomyolipoma in both management and care.

Authors:  Takashi Hatano; Shin Egawa
Journal:  Asian J Surg       Date:  2020-01-17       Impact factor: 2.767

Review 7.  The cutaneous manifestations of tuberous sclerosis complex.

Authors:  Quoc-Bao D Nguyen; Mary D DarConte; Adelaide A Hebert
Journal:  Am J Med Genet C Semin Med Genet       Date:  2018-09-23       Impact factor: 3.908

Review 8.  Renal manifestation of tuberous sclerosis complex.

Authors:  John J Bissler; J Christopher Kingswood
Journal:  Am J Med Genet C Semin Med Genet       Date:  2018-10-11       Impact factor: 3.908

9.  Clinical features and optical coherence tomography findings of retinal astrocytic hamartomas in Chinese patients with tuberous sclerosis complex.

Authors:  Chenxi Zhang; Kaifeng Xu; Qin Long; Zhikun Yang; Rongping Dai; Hong Du; Donghui Li; Zhiqiao Zhang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-01-02       Impact factor: 3.117

10.  Maintenance Therapy With Everolimus for Subependymal Giant Cell Astrocytoma in Patients With Tuberous Sclerosis - Final Results From the EMINENTS Study.

Authors:  Katarzyna Bobeff; Karolina Krajewska; Dobromila Baranska; Katarzyna Kotulska; Sergiusz Jozwiak; Wojciech Mlynarski; Joanna Trelinska
Journal:  Front Neurol       Date:  2021-04-09       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.